J&J, Roche lead January's journal-ad numbers; Novartis nabs new approval for Jakavi; Aussie watchdog to appeal Pfizer ruling;

> Johnson & Johnson ($JNJ) spent more than $2.5 million on medical journal advertising in January, putting itself in line to lead pharma's journal-ad pack as it did in 2014; Roche's ($RHHBY) January numbers came in second at $1.5 million. Release

> Novartis ($NVS) won European approval for Jakavi, its JAK inhibitor, to treat adults with polycythemia vera, a rare and incurable blood cancer. Release

> Pfizer's ($PFE) court fight over Lipitor discounting in Australia isn't over yet; the country's consumer watchdog says it will appeal a federal judge's decision that the company hadn't engaged in anticompetitive conduct. Report

> Boehringer Ingelheim is poised to roll out its idiopathic pulmonary fibrosis drug Ofev in Europe, with an on-sale date in Germany this week. Report

> Teva Pharmaceutical Industries ($TEVA) beefed up its oncology pipeline with a deal to buy four of Ignyta's drug candidates and invest in the biotech drug developer. Release

And Finally... A Novo Nordisk ($NVO) documentary about Type 2 diabetes in Ghana is up for a vote in the annual Boston College Center for Corporate Citizenship Film Festival. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.